Literature DB >> 26611513

Is Surgery Warranted for Oligometastatic Disease?

Tom Treasure1, Fergus Macbeth2.   

Abstract

The development of metastases after curative treatment can be seen as a failure. A common justification for the removal of metastases is that the knowledge that they are there may cause psychological distress, a real symptom that may be relieved by their removal. Although it is a commonly used justification for metastasectomy, the authors are unaware of any studies confirming or quantifying the health gain. This article strongly challenges the belief in clinical effectiveness and demonstrates that it is supported neither by a sound biological rationale nor by any good evidence. Reasons are suggested why this unfounded belief has become so prevalent.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Citation network analysis; Clinical effectiveness; Colorectal cancer; Lung metastasectomy

Mesh:

Year:  2016        PMID: 26611513     DOI: 10.1016/j.thorsurg.2015.09.010

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  4 in total

1.  Surgery and ablative techniques for lung metastases in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial: is there equivalence?

Authors:  Tom Treasure
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Looking forward lung metastasectomy-do we need a staging system for lung metastases?

Authors:  Marcello Migliore; Michel Gonzalez
Journal:  Ann Transl Med       Date:  2016-03

3.  An External-Validated Prediction Model to Predict Lung Metastasis among Osteosarcoma: A Multicenter Analysis Based on Machine Learning.

Authors:  Wenle Li; Wencai Liu; Fida Hussain Memon; Bing Wang; Chan Xu; Shengtao Dong; Haosheng Wang; Zhaohui Hu; Xubin Quan; Yizhuo Deng; Qiang Liu; Shibin Su; Chengliang Yin
Journal:  Comput Intell Neurosci       Date:  2022-05-06

Review 4.  Pulmonary metastasectomy: limits to credibility.

Authors:  Tom Treasure; Fergus Macbeth
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 3.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.